Fast, accurate treatment decisions for NSCLC patients
ASPYRE’s comprehensive lung panel simultaneously analyzes DNA and RNA from blood or tissue in a single assay, enabling straightforward, precise identification of all NCCN guideline recommended genomic biomarkers associated with approved targeted therapies for NSCLC.
Fast time to treatment
ASPYRE-Lung dramatically simplifies and accelerates the detection of actionable biomarkers, enabling you to identify targeted treatment options within days of diagnosis.
Reduced sample requirement
ASPYRE’s high sensitivity enables testing from tissue samples with as little as 10% tumor content, compared to 20% or 30% for most competing assays.
Actionable results
ASPYRE accelerates and simplifies analysis by eliminating the noise from genomic data, ensuring accuracy for the markers that are of interest, to enable more confident decision-making.
Ultra-sensitive
ASPYRE’s high sensitivity enables accurate biomarker analysis from blood or tissue, even from limited samples with low tumor content.
Biomarkers included in ASPYRE-Lung
ASPYRE-Lung enables the simultaneous analysis of 77 DNA mutations & 37 RNA fusions.
DNA
EGFR
Exon 18
G719A
G719S
G719C
Exon 19
Deletions
Insertions
Exon 20
T790M
S7681
C797S
Insertions
Exon 21
L858R
L861Q
BRAF
Exon 15
V600E
KRAS
Exon 2
G12A
G12C
G12D
G12F
G12R
G12S
G12V
Exon 2
G13A
G13C
G13D
G13R
G13S
Exon 3
Q61E
Q61H
Q61K
Q61L
Q61R
ERBB2
Exon 17
V659E
Exon 20
Insertions
RNA
ALK
RET
MET
NTRK1
NTRK2
NTRK3
ROS1
Featured resources & publications
The ASPYRE technology
Read more about how the unique molecular biology behind ASPYRE overcomes the limitations of PCR and NGS to increase access to comprehensive biomarker testing.
Ultra-sensitive molecular detection of gene fusions from RNA using ASPYRE
Gray et al, BMC Medical Genomics | (2022) 15:215
Single-copy detection of somatic variants from solid and liquid biopsy
A-L. Silva et al, Scientific Reports | (2021) 11:6068
Introducing ASPYRE-Lung
By simplifying the detection of genomic biomarkers from either tissue or blood, use of ASPYRE-Lung as a first-line diagnostic helps identify those NSCLC patients who will likely benefit from precision medicine in a fraction of the time and at a fraction of the cost of NGS.
